LAUSR

Dear Editor, Androgenetic alopecia (AGA) is one of the most common diagnosis in a hair clinic. It is nonscarring pattern hair loss that affects individuals, independent on severity, age, and gender (Krabcov a, 2017). The physical aspect of AGA is characterized by progressive miniaturization of scalp hair follicles (Prager, Bickett, French, & Marcovici, 2006). Evidence in support of new treatments is limited. However, therapeutics which reverse the androgen-driven inhibition of hair follicle signaling pathways, such as prostaglandin analogs and antagonists, are the likely near future direction of AGA treatment development (Guo, Gao, Endo, & McElwee, 2017). It was supposed that prostaglandins would have an important role in the hair growth; PGE and PGF2a play a generally positive role on the hair growth, while PGD2 an inhibitory role on the hair growth (Garza et al., 2012). Food and Drug Administration approved PGF2a analogous (latanoprost) to be used clinically to enhance hair growth of human eyelashes (Faghihi, Andalib, & Asilian, 2009). Recently, Rossi et al. (2017) provided a preliminary study on the therapeutic efficacy of topical cetirizine 1% lotion applied once a day on the scalp, in management of AGA. The authors recruited 85 patients (male and female patients), of which 67 were used topical cetirizine, while 18 were control patients. Studies investigating the anti-inflammatory/antiallergic effects of cetirizine have indicated that it may exhibit antiinflammatory properties independent of its H1 effects (Chen, 2008). In this regard, Rossi et al. (2017) stated that inhibition of PGD2 (as di-hydroxytestosterone) through the use of cetirizine is a further pathogenic clue in AGA, resulting to be a new and promising target treatment for AGA (Rossi et al., 2017). Authors observed that the main effect of cetirizine was an increase in total hair density, terminal hair density, and diameter variation. Topical cetirizine may be a promising therapy for AGA with excellent safety profile. Further studies are warranted to assess the insight action of the drug, the possible role of other H1-blockers and whether it is effective in other forms of alopecias.